New Pulmozyme Research Data Posted: 01-22-07 17:08pm
Genentech inc., of south san francisco,
said data reported at the north america
cystic fibrosis conference in denver
showed that pulmozyme (dornase alfa,
recombinant) slowed the rate of lung
function declines in cf patients. The
evaluation was conducted through a review
of patient data from a phase iv
observational study, the epidemiologic
study of cystic fibrosis. The rate of
decline in lung function was evaluated in
1,991 patients who had not received
pulmozyme for two years, received
pulmozyme and remained on it for 80
percent of the time for the following two
years, compared to 3,108 cystic fibrosis
patients who never received the drug. The
mean rate of decline for pulmozyme
patients was reduced by 46 percent
(p<0.001) during the two years of drug
use, with no change in the comparator
group. In addition to demonstrating the
slower rate of lung function decline in
those who received pulmozyme, they also
had an immediate improvement in lung
function compared to those not treated
with the drug.
The site is not a replacement for professional medical opinion, examination, diagnosis or treatment. Always seek the advice of your medical doctor or other qualified health professional before starting any new treatment or making any changes to existing treatment. Do not delay seeking or disregard medical advice based on information written by any author on this site. No health questions and information on eHealth Forum is regulated or evaluated by the Food and Drug Administration and therefore the information should not be used to diagnose, treat, cure or prevent any disease without the supervision of a medical doctor. Posts made to these forums express the views and opinions of the author, and not the administrators, moderators, or editorial staff and hence eHealth Forum and its principals will accept no liabilities or responsibilities for the statements made.
Schizophreniahealth
This page was last updated on June 11, 2008
